These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7812072)

  • 1. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients.
    Chevalley T; Rizzoli R; Nydegger V; Slosman D; Rapin CH; Michel JP; Vasey H; Bonjour JP
    Osteoporos Int; 1994 Sep; 4(5):245-52. PubMed ID: 7812072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
    Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture.
    Fujita T; Ohue M; Fujii Y; Miyauchi A; Takagi Y
    J Bone Miner Metab; 2004; 22(1):32-8. PubMed ID: 14691684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.
    Sugimoto T; Matsumoto T; Hosoi T; Shiraki M; Kobayashi M; Okubo N; Takami H; Nakamura T
    J Bone Miner Metab; 2020 Nov; 38(6):848-858. PubMed ID: 32671481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur.
    Chevalley T; Rizzoli R; Nydegger V; Slosman D; Tkatch L; Rapin CH; Vasey H; Bonjour JP
    Osteoporos Int; 1991 Jun; 1(3):147-54. PubMed ID: 1790402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
    Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
    Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K; Byrjalsen I; Andersen JR; Bihlet AR; Russo LA; Alexandersen P; Valter I; Qvist P; Lau E; Riis BJ; Christiansen C; Karsdal MA;
    Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    Cummings SR; Black DM; Thompson DE; Applegate WB; Barrett-Connor E; Musliner TA; Palermo L; Prineas R; Rubin SM; Scott JC; Vogt T; Wallace R; Yates AJ; LaCroix AZ
    JAMA; 1998 Dec 23-30; 280(24):2077-82. PubMed ID: 9875874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new predictive index for vertebral fractures: the sum of the anterior vertebral body heights.
    Diacinti D; Pisani D; Barone-Adesi F; Del Fiacco R; Minisola S; David V; Aliberti G; Mazzuoli GF
    Bone; 2010 Mar; 46(3):768-73. PubMed ID: 19895914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive effects of a chicken eggshell powder-enriched vitamin-mineral supplement on femoral neck bone mineral density in healthy late post-menopausal Dutch women.
    Schaafsma A; van Doormaal JJ; Muskiet FA; Hofstede GJ; Pakan I; van der Veer E
    Br J Nutr; 2002 Mar; 87(3):267-75. PubMed ID: 12064336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
    Guaydier-Souquières G; Kotzki PO; Sabatier JP; Basse-Cathalinat B; Loeb G
    Osteoporos Int; 1996; 6(2):171-7. PubMed ID: 8704358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.